September 11, 2019 01:46 PM EDTUpdated September 12, 10:24 AM
Bioregnum
Opinion

In­vestors lost big as Alzheimer’s R&D went over the cliff in 2019. Will they ever come back?

Neu­rotrope this week joined the long line of bio­phar­ma com­pa­nies that have been mauled by clin­i­cal fail­ure for Alzheimer’s drugs. But their crushed shares …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times